Working… Menu
Trial record 87 of 179 for:    LENALIDOMIDE AND Leukemia

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial (RESPeCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01127542
Recruitment Status : Terminated (Potential safety issue of second primary malignancies in patients treated with lenalidomide.)
First Posted : May 21, 2010
Last Update Posted : December 5, 2011
Celgene Corporation
Leukemia Research Fund
Information provided by:
The Christie NHS Foundation Trust

Brief Summary:
The majority of patients with CLL are diagnosed with early stage disease (Binet stage A or Rai stage 0/I). Standard management of such patients is observation, and with median age at diagnosis of 72 and median time to progression of >5-10 years, many will never require treatment. In contrast, a proportion of patients have more aggressive disease, and over the last decade, a number of molecular factors have been identified that may be used to identify patients with poor prognosis disease . Each is associated with shortened time to treatment (typically less than 3 years in patients with 2 of more factors), reduced survival, with in the case of p53/ATM inactivation, resistance to treatment. Whether it is possible to improve the outcome of patients with CLL and adverse prognostic factors by early intervention with treatment is unknown. Several trials in the 1980's demonstrated that treatment of stage A CLL with conventional chemotherapy (chlorambucil) did not alter the natural history of the disease, although none of these studies stratified patients according to risk. The choice of alternative potential therapeutic agents is limited; they should be effective in patients with adverse prognostic factors, have acceptable toxicity, be able to overcome the drug resistance associated with p53/ATM inactivation and ideally be orally administered. Two recent phase II trials have demonstrated that Lenalidomide is effective in the treatment of relapsed/refractory disease. Importantly, both studies included a high proportion of patients with adverse prognostic factors including p53 inactivation. The principle objective of this study is to investigate the efficacy of Lenalidomide in achieving disease response (complete remission and clearance of minimal residual disease) in patients with poor risk early stage disease, together with assessment of safety and tolerability.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukaemia Drug: Lenalidomide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm Phase II Study to Investigate the Use of Lenalidomide in the Treatment of Patients With Early Stage CLL Associated With Poor Prognostic Factors
Study Start Date : May 2010
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: Lenalidomide for early stage poor prognosis CLL Drug: Lenalidomide
Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
Other Names:
  • Revlimid
  • CC-5013

Primary Outcome Measures :
  1. Complete Remission with clearance of Minimal Residual Disease (MRD) [ Time Frame: 6 months (or earlier if clinically indicated) ]

Secondary Outcome Measures :
  1. Event free survival [ Time Frame: Treatment/ progression/ death details collected at all visits (6 visits per month in dose escalation, 1 visit per month in dose maintenance, annual in long-term follow-up) ]
    Defined as interval from the first treatment day to the first sign of disease progression, treatment for relapse or death (whichever occurs first).

  2. Safety & tolerability of treatment (occurrence of adverse events) [ Time Frame: Assessed at all visits (6 visits per month in dose escalation, 1 visit per month in dose maintenance, annual in long-term follow-up) ]
    Adverse events will be monitored according to NCI CTCAE v3 from screening until 1 month after treatment discontinuation/ trial closure. Adverse event data will be captured at all visits (6 visits per month in dose escalation, 1 visit per month in dose maintenance). Adverse event data will be assessed by blood tests, physical exam/ vital signs and pregnancy testing.

  3. Time to next treatment [ Time Frame: Treatment details collected at all visits (6 visits per month in dose escalation, 1 visit per month in dose maintenance, annual in long-term follow-up) ]
    Defined as interval between first treatment day on the study protocol to the first day of the next course of CLL therapy following disease progression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Binet stage A CLL
  • 2 or more risk factors:
  • Unmutated IgVH locus (≥98% homology to germline sequence)
  • CD38 expression (>7%)
  • Deletion of chromosome 11q22 (>20% by FISH)
  • Deletion of chromosome 17p13 (>10% by FISH)
  • Over 18 years old
  • Capable to provide written informed consent
  • ECOG performance status < 2
  • Life expectancy > 2 years
  • Must agree to not share lenalidomide with someone else
  • Must agree not to donate blood whilst taking the study drug and for one week after discontinuation of treatment.
  • Female subjects of childbearing potential and all male subjects must agree to comply with the stipulations of the pregnancy prevention plan.

Exclusion Criteria:

  • Current or recent (within the last 1 month) participation in another clinical trial investigating the action of an investigational medicinal product for the treatment of CLL
  • Pregnant or lactating
  • Known positivity for human immunodeficiency virus (HIV) types 1 or 2
  • Prior history of malignancies, other than CLL, unless the subject was treated with curative intent and has been free of the disease for ≥3 years. Exceptions include the following:
  • Basal cell carcinoma of the skin
  • Squamous cell carcinoma of the skin
  • Carcinoma in situ of the cervix
  • Carcinoma in situ of the breast
  • Significantly abnormal renal or hepatic function (creatinine clearance < 60ml/min, serum aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), serum bilirubin > 34μmol/l)
  • Laboratory tumour lysis syndrome according to the Cairo-Bishop classification. Subjects may be enrolled when these abnormalities have been corrected.
  • Peripheral neuropathy (grade ≥ 2)
  • Previous treatment for CLL
  • Previous treatment with Thalidomide or immunomodulatory derivative drugs (including Lenalidomide)
  • Treatment with corticosteroids (for CLL or other indications) < 28 days from study entry
  • Evidence of Richter's transformation
  • Unsupported absolute neutrophil count < 1x109/l or platelet count < 50x10*9/l not due to CLL
  • Active autoimmune haemolytic anaemia or thrombocytopenia
  • Any other medical or psychological condition that in the view of the investigator would be likely to impact compliance with the protocol or interfere with trial treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01127542

Layout table for location information
United Kingdom
The Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom, BH7 7DW
Heart of England NHS Foundation Trust
Birmingham, United Kingdom, B9 5SS
Addenbrooke's Hospital
Cambridge, United Kingdom, CB2 0QQ
University Hospital of Wales
Cardiff, United Kingdom, CF14 4XW
St James's University Hospital
Leeds, United Kingdom, LS9 7TF
The Royal Liverpool and Broadgreen University Hospital
Liverpool, United Kingdom, L7 8XP
King's College Hospital
London, United Kingdom, SE5 9RS
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Mid Yorkshire Hospitals NHS Trust
Wakefield, United Kingdom, WF1 4DG
Sponsors and Collaborators
The Christie NHS Foundation Trust
Celgene Corporation
Leukemia Research Fund
Layout table for investigator information
Principal Investigator: Adrian Bloor The Christie NHS Foundation Trust

Layout table for additonal information
Responsible Party: Angela Ball, R&D manager, The Christie NHS Foundation Trust Identifier: NCT01127542     History of Changes
Other Study ID Numbers: 09_DOG06_99
2009-011078-14 ( EudraCT Number )
ISRCTN ( Registry Identifier: ISRCTN84606869 )
First Posted: May 21, 2010    Key Record Dates
Last Update Posted: December 5, 2011
Last Verified: December 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents